Filling the need for trusted information on national health issues

The Opioid Epidemic and Medicaid's Role in Facilitating Access to Treatment

Issue Brief
  1. Opioid use disorder is defined as the dependence or abuse of opioids in the past year.

    ← Return to text

  2. Kaiser Family Foundation analysis of the 2017 National Survey on Drug Use and Health (NSDUH).

    ← Return to text

  3. Jarlenski, M., Barry, C. L., Gollust, S., Graves, A. J., Kennedy-Hendricks, A., & Kozhimannil, K. (2017). Polysubstance Use Among US Women of Reproductive Age Who Use Opioids for Nonmedical Reasons. American journal of public health, 107(8), 1308–1310. doi:10.2105/AJPH.2017.303825, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508143/.

    ← Return to text

  4. Kaiser Family Foundation analysis of the 2017 National Survey on Drug Use and Health (NSDUH).

    ← Return to text

  5. “Medication-Assisted Treatment (MAT),” SAMHSA (Substance Abuse and Mental Health Services Administration), available at: https://www.samhsa.gov/medication-assisted-treatment/.

    ← Return to text

  6. Kathleen Gifford, et al., “States Focus on Quality and Outcomes Amid Waiver Changes: Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2018 and 2019,” (Washington, DC: Kaiser Family Foundation, October 2018), https://www.kff.org/medicaid/report/states-focus-on-quality-and-outcomes-amid-waiver-changes-results-from-a-50-state-medicaid-budget-survey-for-state-fiscal-years-2018-and-2019/.

    ← Return to text

  7. Medicaid and CHIP Payment and Access Commission, State Policies for Behavioral Health Services Covered Under the State Plan (Washington, DC: Medicaid and CHIP Payment and Access Commission, June 2016), https://www.macpac.gov/publication/behavioral-health-state-plan-services/,

    ← Return to text

  8. An IMD is a “hospital, nursing facility, or other institution of more than 16 beds, that is primarily engaged in providing diagnosis, treatment, or care of persons with mental diseases [sic], including medical attention, nursing care, and related services.” 42 U.S.C. § 1396d (i).

    ← Return to text

  9. David G. Smith and Judith D. Moore, Medicaid Politics and Policy, at 188-89 (2008); see also CMS Medicaid Manual § 4309 (A)(2), https://www.cms.gov/Regulations-and-Guidance/guidance/Manuals/Paper-Based-Manuals-Items/CMS021927.html.

    ← Return to text

  10. Julia Paradise and MaryBeth Musumeci, “CMS’s Final Rule on Medicaid Managed Care: A Summary of Major Provisions,” Kaiser Family Foundation, accessed April 2018, https://www.kff.org/medicaid/issue-brief/cmss-final-rule-on-medicaid-managed-care-a-summary-of-major-provisions/,

    ← Return to text

  11. CMS, New Service Delivery Opportunities for Individuals with a Substance Use Disorder, SMD #15-003, (July 27, 2015), https://www.medicaid.gov/federal-policy-guidance/downloads/smd15003.pdf.

    ← Return to text

  12. CMS, Strategies to Address the Opioid Epidemic, SMD #17-003 (Nov. 1, 2017), https://www.medicaid.gov/federal-policy-guidance/downloads/smd17003.pdf.

    ← Return to text

  13. Elizabeth Hinton, MaryBeth Musumeci, Robin Rudowitz, Larisa Antonisse, and Cornelia Hall, “Section 1115 Medicaid Demonstration Waivers: The Current Landscape of Approved and Pending Waivers,” (Washington, DC: Kaiser Family Foundation, February 2019), https://www.kff.org/medicaid/issue-brief/section-1115-medicaid-demonstration-waivers-the-current-landscape-of-approved-and-pending-waivers/.

    ← Return to text

  14. The 30 days do not need to be consecutive. H.R. 6, § 5052 (a)(2) (creating new Social Security Act § 1915 (l)(2)).

    ← Return to text

  15. H.R. 6, § § 5051-5052; see also Kaiser Family Foundation, Federal Legislation to Address the Opioid Crisis: Medicaid Provisions in the SUPPORT Act (Oct. 2018), https://www.kff.org/medicaid/issue-brief/federal-legislation-to-address-the-opioid-crisis-medicaid-provisions-in-the-support-act/.

    ← Return to text

  16. Kaiser Family Foundation, “Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State,” (Washington, DC: Kaiser Family Foundation, April 18, 2019), https://www.kff.org/medicaid/issue-brief/medicaid-waiver-tracker-approved-and-pending-section-1115-waivers-by-state/.

    ← Return to text

  17. Tami L. Mark, et al., “Insurance Financing Increased For Mental Health Conditions But Not For Substance Use Disorders, 1986-2014,” Health Affairs 35, no. 6 (June 2016):958-965.

    ← Return to text

  18. Substance Abuse and Mental Health Services Administration. Projections of National Expenditures for Treatment of Mental and Substance Use Disorders, 2010–2020. HHS Publication No. SMA-14-4883. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014, https://store.samhsa.gov/system/files/sma14-4883.pdf.

    ← Return to text

  19. “Synthetic Opioid Data,” Centers for Disease Control and Prevention, December 2018, https://www.cdc.gov/drugoverdose/data/fentanyl.html.

    ← Return to text